This episode delves into India's current regulatory landscape, focusing on key sectors such as Trade Remedy, pharmaceutical amendments, and international compliance frameworks.

Major updates include the launch of multiple anti-dumping investigations by India’s Ministry of Commerce and Industry targeting imports like antioxidants, Resorcinol, nylon films, and sodium nitrite from countries including China, Japan, South Korea, and Thailand. These investigations mandate stakeholder submissions via official portals within 37 days.

Another significant development is the Securities and Exchange Board of India’s proposal for a common advertisement code and the Integrated or Regulatory Sandbox framework (IoRS), designed to streamline testing of hybrid financial products under multiple regulators.

Additionally, the Indian Pharmacopoeia Commission has issued amendment lists and errata for the 2026 edition, emphasizing biotechnology-derived therapeutics and vaccine monographs, urging stakeholders to adopt these updates.

For more information, visit the Carver Agents website.

Articles mentioned:

1. 印度对涉华抗氧化剂启动反倾销调查
2. 印度对涉华间苯二酚启动反倾销调查
3. 印度对涉华双向拉伸尼龙薄膜启动反倾销调查
4. 印度对华亚硝酸钠启动反倾销调查
5. 印度对华装饰纸启动第一次反倾销日落复审调查
6. Indian Pharmacopoeia 2026- Amendment Lists
7. Sudan-related Designations
8. 日・インド間の二国間クレジット制度（JCM）の実施規則（RoI : Rule of Implementation）を策定しました
9. 36/2026 - 23.06.2026 - SEBI Proposes Common Advertisement Code for Specified Regulated Entities
10. 印度对涉华合金和非合金热轧钢板启动反倾销调查